GlaxoSmithKline Reports Strong Q1 2025 Results Driven by Asthma and HIV Drug Sales

GSK is in talks to acquire Nuvalent, a biotech company specializing in cancer treatment. The deal could be worth over $9 billion, the largest in GSK's history.